Sg3 Management, LLC Mirati Therapeutics, Inc. Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $165,080 - $394,480	4,000 New	4,000 $181,000
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $391,599 - $887,099	-10,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $341,189 - $679,365	4,500 Added 81.82%	10,000 $822,000
Q4 2021 Feb 15, 2022	SELL	$132.01 - $190.29 $1.12 Million - $1.62 Million	-8,500 Reduced 60.71%	5,500 $807,000
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $1.59 Million - $2.13 Million	12,000 Added 600.0%	14,000 $2.48 Million
Q3 2020 Nov 13, 2020	SELL	$113.26 - $167.27 $622,930 - $919,985	-5,500 Reduced 73.33%	2,000 $332,000
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $144,020 - $240,780	2,000 Added 36.36%	7,500 $856,000
Q1 2020 May 12, 2020	BUY	$69.78 - $116.21 $383,790 - $639,155	5,500 New	5,500 $423,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.